Clinical trial documentation is crucial for patient safety, compliance with Good Clinical Practice, and the validity of research findings and treatments. It enables ongoing monitoring of the study and helps identify inconsistencies with the protocol. However, even minor issues can lead to rejection by regulatory authorities.

Data quality issues in clinical trial documentation

Poor data quality does not only delay study progress but, above all, can lead to incorrect conclusions regarding patient safety, the effectiveness of the investigational medicinal product, and overall study outcomes. One of the most common issues affecting data quality is the inappropriate or inconsistent completion of documentation. This may result from an overly complex protocol, lack of clear structure, or inappropriate delegation of tasks within the study team. Additionally, if the study team has not received adequate training before the study begins, they may rely on their own judgement rather than referring to the protocol.

Inconsistencies across clinical trial documents

Inconsistencies in clinical trial documentation are a common reason for rejection by regulatory authorities. Some of these issues may be identified during monitoring; however, as eCRF data are often checked on a sample basis, not all errors are detected. Even if the documentation is not formally rejected, remaining inconsistencies can compromise data quality and reduce the overall reliability of the study.

Another example of inconsistency is a lack of chronological order and incomplete entries. This is often the result of delays in documentation or missing data. In studies involving a large number of participants, it may be difficult to accurately recall all results and relevant information. Similar issues arise in adverse event reporting, where events may be recorded in medical records but not reflected in the eCRF, or where dates of occurrence differ between sources.

Less obvious inconsistencies may arise during translation, particularly when a translator or proofreader attempts to ‘improve’ the text by introducing synonyms. This is a common issue among less experienced translators, who may not realise that consistency is more important than stylistic variation in clinical documentation. As a result, even well-prepared source documentation may become non-compliant after translation. Regulatory authorities expect strict consistency across all clinical trial documents, and even minor discrepancies may lead to queries or delays.

Non-compliance with regulatory requirements

Regulatory authorities such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) define requirements regarding the types of documents required in clinical trials and the sections they must include. In addition, both authorities follow Good Clinical Practice (GCP) guidelines, which establish an international standard for the design, conduct and reporting of clinical studies. These requirements ensure that clinical trial documentation is clear, consistent and suitable for use across different regulatory environments. They also define the expected structure, terminology and formatting of documents.

Failure to comply with these requirements may result in the rejection of clinical trial documentation, as well as the invalidation of study findings and potential risks to patient safety. In such cases, the study results may be considered unreliable, inaccurate or insufficient to support the efficacy and safety of the investigational medicinal product. Consequently, this may lead to the need to repeat part or all of the study, delays in product development, and the inability to publish or use the study results for regulatory approval.

Unclear or poorly structured clinical information

Unclear or poorly structured clinical information may have consequences similar to those resulting from data inconsistencies or non-compliance. One common issue is the use of overly complex language. In some cases, researchers attempt to make the text sound more scientific by adding unnecessary phrases, which can hinder understanding. However, regulatory authorities require that information be presented in a clear and accessible manner, particularly in documents intended for study participants.

Incoherence within clinical trial documentation can have serious implications for patient treatment and safety. The most common causes include poor version control, transcription errors, and fragmented data collection. These issues may lead to discrepancies between documents and reduce the reliability of the study data.

In addition, when data are presented in an overly complex or unnecessarily sophisticated way, they may become difficult to interpret. The combination of inconsistent data, high data volume, and complex structure further hampers clarity and increases the risk of misinterpretation.

Consequences of rejected clinical trial documentation

As mentioned above, the rejection of clinical trial documentation may result in study results being considered unreliable, inaccurate or insufficient to support the efficacy and safety of the investigational medicinal product. In addition, the study may be temporarily halted or terminated early, which can impact access to new treatment options and limit the possibility of using potentially more effective medical products.

It also leads to additional costs, delays and the need for extensive revisions. Sponsors may be required to update or resubmit documentation, respond to regulatory queries, and repeat parts of the study. This can significantly extend timelines and increase the overall cost of clinical development. In some cases, delayed or rejected documentation may affect the competitive position of a product and postpone its entry to the market.

How to prevent rejection of clinical trial documentation

First of all, preventing the rejection of clinical trial documentation requires strict adherence to Good Clinical Practice (GCP) guidelines. It is also essential to pay close attention to detail and ensure effective data quality management. Documentation must be complete, consistent with the clinical study protocol and regulatory requirements, and based on high-quality data.

In addition, clear structure and consistency across all clinical trial documents are essential. Standardised terminology, proper version control and accurate data transcription help minimise the risk of inconsistencies and errors. Regular review of documentation throughout the study also plays a key role in identifying and addressing issues at an early stage.

The involvement of experienced medical writers, editors and translators further supports the quality and compliance of clinical trial documentation. They ensure that complex clinical data are presented in a clear, accurate and consistent manner, aligned with regulatory expectations. This not only reduces the risk of rejection but also facilitates smoother regulatory review and faster approval timelines.